GC-rich sequences present in cfDNA stimulate endogenous stems cells when body is exposed to adverse conditions. GC-rich fragments of human DNA may be used for preconditioning of therapeutic MSCs aiming at an increase in their survival in the ailing body.

Abstract:The article deals with the comparative contests ratios of judoists -men representing the Russian Federation and Kyrgyzstan at national and international competitions. The competition bouts of 146 athletes competing in weight categories up to 60 and 66 kg were analyzed for 2 time periods: from 2003 to 2009 and from 2010 to 2015. Moreover, the separation for periods is associated with the introduction of significant changes in the rules of judo competition aimed to encourage athletes to conduct a dynamic and attacking struggle. The purpose of the research was to reveal the fitness of the athletes to conduct an active attack on the modified rules of the competition. Besides, the results of the analysis conducted by the authors show that the judoists in the category up to 60 kg in the second time period is a significant increase in such competitive factors as the number of common technical (P <0.01) and successful (P <0.05) groundwork. It should also be noted the decrease in time intervals between attacking actions is an average of 16 seconds and a decrease in the number of lost technical actions of athletes in a wrestling (P <0.001). Meanwhile, the athletes competing in the category up to 66 kg showed a significant decrease in both the total (P <0.01) and the successful (P <0.001) number of technical actions in the wrestling. Some increase in the rates is fixed in the number of moves performed by wrestlers in the ground fighting but the data does not contain significant differences. In general, the experts believe that the majority of athletes of this weight category formed a defensive style of fighting which does not correspond to the views of experts and judges on the modern judo. The trainers and athletes should make certain adjustments to the tactics of constructing a competitive bout.

Silver nanoparticles (AgNPs) are the most widely studied antimicrobial nanomaterials. However, their use in biomedicine is currently limited due to the availability of data that prove the nanosilver toxicity associated primarily with oxidative stress development in mammalian cells. The surface modification of AgNPs is a potent technique of improvement of their biocompatibility. The synthetic or natural compounds that combine zero or low toxicity towards human and animal organisms with inherent antimicrobial properties are the most promising stabilizing agents, their use would also minimize the risks of microorganisms developing resistance to silver-based materials. We used a simple technique to obtain 30–60 nm AgNPs stabilized with benzyldimethyl[3-myristoylamine)-propyl]ammonium chloride monohydrate (BAC)—a well-known active ingredient of many antibacterial drugs. The objective of the study was to assess the AgNPs-BAC entero- and hepatotoxicity to CBF1 mice upon enteral administration. The animals were exposed to 0.8–7.5 mg/kg doses of AgNPs-BAC in the acute and to 0.05–2.25 mg/kg doses of AgNPs-BAC in the subacute experiments. No significant entero- and hepatotoxic effects following a single exposure to doses smaller than 4 mg/kg were detected. Repeated exposure to the doses of AgNPs-BAC below 0.45 mg/kg and to the doses of BAC below 0.5 mg/kg upon enteral administration also led to no adverse effects. During the acute experiment, the higher AgNPs-BAC dose resulted in increased quantities of aminotransferases and urea, as well as the albumin-globulin ratio shift, which are indicative of inflammatory processes. Besides, the relative mass of the liver of mice was smaller compared to the control. During the subacute experiment, the groups treated with the 0.25–2.25 mg/kg dose of AgNPs-BAC had a lower weight gain rate compared to the control, while the groups treated with the 2.25 mg/kg dose of AgNPs-BAC showed statistically significant variations in the blood serum transaminases activity, which indicated hepatosis. It should be noted that the spleen and liver of the animals from the groups treated with the 0.45 and 2.25 mg/kg dose of AgNPs-BAC were more than two times smaller compared to the control. In the intestines of some animals from the group treated with the 2.25 mg/kg dose of AgNPs-BAC small areas of hyperemia and enlarged Peyer’s patches were observed. Histological examination confirmed the initial stages of the liver and intestinal wall inflammation.

Increased interest in nanosilver during the last 10 years is mainly explained by the emergence and spread of pathogenic microorganisms with multiple drug resistance, including resistance to last-generation antibiotics. In this article, we for the first time, give a description of large-scale clinical trials of a new nanosilver based antibacterial drug [containing two active components: silver nanoparticles (AgNPs) (10–50 ppm) and benzyldimethyl[3-(miristoylamino)-propyl]ammonium chloride (100 ppm)] registered in Russia in 2015 as a veterinary drug under the brand name Argumistin™. This drug has been approved for application in a diluted dosage form – as eye drops, intranasal drops and orally; it has also been approved for application in a more concentrated dosage form (up to 50 ppm of nanosilver) as ear drops and as an antiseptic during demodicosis and gum disease treatment, open wound treatment, etc. We have registered the high therapeutic effectiveness of Argumistin™ during treatment of infectious conjunctivitis, gingivitis, parodontosis and enteritis of dogs. Application of this antibacterial drug gives considerable (up to 70% in case of periodontal diseases) reduction in the treatment period and prevention of complications. The results of clinical trials in the treatment of infectious diseases of dogs makes Argumistin™ a promising candidate for an effective antibacterial drug for human medicine.